secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2026-08-12T20:15:36+00:00
Accession:  0001193125-26-346888
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports Q2 net loss $32.9M; HCV Phase 3 C-BEYOND hits primary endpoint
---------------------------------------------------------------------------

- Net loss $32.9M ($0.41/sh) vs $37.2M ($0.44/sh) in Q2 2025; cash & investments $219.5M, down from $301.8M at year-end 2025.
- C-BEYOND met primary non-inferiority endpoint: BEM/RZR SVR 93.9% vs SOF/VEL 94.8% in mITT (n=905); SVR 93.5% in non-cirrhotics with 8-week regimen.
- C-FORWARD enrollment completed (880+ patients, 17 countries); topline expected early Q1 2027; NDA submission anticipated Q2 2027.
- AT-587 Phase 1 trial initiated in July 2026 for hepatitis E virus; no approved HEV therapy exists.
- R&D expenses $28.2M in Q2 2026, down from $32.3M year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/0001193125-26-346888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/d165663d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-346888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer